Zhong Guo Jing Ji Wang·2025-09-29 09:45Core Viewpoint - Huyou Pharmaceutical's stock has experienced a decline, currently trading at 21.45 yuan, down 3.81%, indicating a state of breaking [1] Group 1: Company Overview - Huyou Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 26, 2021, with an initial public offering of 63.6 million shares at a price of 38.87 yuan per share [1] - The company raised a total of 2.472 billion yuan, with a net amount of 2.361 billion yuan after deducting issuance costs, exceeding the original fundraising plan by 453 million yuan [2] Group 2: Financial Performance - From 2021 to 2023, the company's operating revenues were 1.824 billion yuan, 1.493 billion yuan, and 927 million yuan, while net profits attributable to shareholders were 446 million yuan, 249 million yuan, and 140 million yuan respectively [3] - In 2024, the company achieved an operating revenue of 1.094 billion yuan, a year-on-year increase of 18.05%, and a net profit of 325 million yuan, a significant increase of 132.78% [3] - For the first half of 2025, the company reported an operating revenue of 453 million yuan, a year-on-year decrease of 14.86%, and a net loss of 80.72 million yuan compared to a profit of 65.21 million yuan in the same period last year [4]